Key features and details
- Goat polyclonal to alpha 1 Antitrypsin (HRP)
- Suitable for: ICC/IF, WB, ELISA, IHC-Fr, Immunomicroscopy, Dot blot
- Reacts with: Human
- Conjugation: HRP
- Isotype: IgG
Product nameAnti-alpha 1 Antitrypsin antibody (HRP)
See all alpha 1 Antitrypsin primary antibodies
DescriptionGoat polyclonal to alpha 1 Antitrypsin (HRP)
Tested applicationsSuitable for: ICC/IF, WB, ELISA, IHC-Fr, Immunomicroscopy, Dot blotmore details
Species reactivityReacts with: Human
- WB: Human plasma. ICC/IF: MCF7 cells.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Gentamicin sulphate
Constituents: 0.88% Sodium chloride, 1% BSA, 0.42% Potassium phosphate
Concentration information loading...
Purification notesThis product is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against buffer.
- TMB ELISA Substrate (Highest Sensitivity) (ab171522)
- TMB ELISA Substrate (High Sensitivity) (ab171523)
- TMB ELISA Substrate (Fast Kinetic Rate) (ab171524)
- TMB ELISA Substrate (Slow Kinetic Rate) (ab171525)
- TMB ELISA Substrate (Slower Kinetic Rate) (ab171526)
- TMB ELISA Substrate (Slowest Kinetic Rate) (ab171527)
- 450 nm Stop Solution for TMB Substrate (ab171529)
- 650 nm Stop Solution for TMB Substrate (ab171531)
- Immunoassay Blocking Buffer (ab171534)
- Immunoassay Blocking (BSA Free) (ab171535)
Our Abpromise guarantee covers the use of ab191350 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 10 µg/ml.|
|WB||Use at an assay dependent concentration. Detects a band of approximately 55 kDa (predicted molecular weight: 47 kDa).|
|ELISA||Use at an assay dependent concentration.|
|IHC-Fr||Use at an assay dependent concentration.|
|Immunomicroscopy||Use at an assay dependent concentration.|
|Dot blot||Use at an assay dependent concentration.|
FunctionInhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.
Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).
Tissue specificityUbiquitous. Expressed in leukocytes and plasma.
Involvement in diseaseAlpha-1-antitrypsin deficiency
Sequence similaritiesBelongs to the serpin family.
DomainThe reactive center loop (RCL) extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site within the RCL, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable.
modificationsN-glycosylated. Differential glycosylation produces a number of isoforms. N-linked glycan at Asn-107 is alternatively di-antennary, tri-antennary or tetra-antennary. The glycan at Asn-70 is di-antennary with trace amounts of tri-antennary. Glycan at Asn-271 is exclusively di-antennary. Structure of glycans at Asn-70 and Asn-271 is Hex5HexNAc4. The structure of the antennae is Neu5Ac(alpha1-6)Gal(beta1-4)GlcNAc attached to the core structure Man(alpha1-6)[Man(alpha1-3)]Man(beta1-4)GlcNAc(beta1-4)GlcNAc. Some antennae are fucosylated, which forms a Lewis-X determinant.
Proteolytic processing may yield the truncated form that ranges from Asp-30 to Lys-418.
Cellular localizationSecreted. Endoplasmic reticulum. The S and Z allele are not secreted effectively and accumulate intracellularly in the endoplasmic reticulum and Secreted, extracellular space, extracellular matrix.
- Information by UniProt
- A1A antibody
- A1AT antibody
- A1AT_HUMAN antibody
Anti-alpha 1 Antitrypsin antibody (HRP) (ab191350) at 1/5000 dilution + Human Plasma Total Protein at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 47 kDa
Observed band size: 55 kDa why is the actual band size different from the predicted?
Exposure time: 20 seconds
Alpha I Antitrypsin contains three potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
ICC/IF image of ab191350 stained MCF7 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab191350, 10µg/ml) overnight at +4°C. The secondary antibody (green) was ab96931, DyLight® 488 donkey anti-goat IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
ab191350 has been referenced in 6 publications.
- Borel F et al. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of a-1 Antitrypsin Deficiency. Mol Ther 25:2477-2489 (2017). PubMed: 29032169
- Li C et al. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci U S A 108:14258-63 (2011). PubMed: 21844342
- Chulay JD et al. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 22:155-65 (2011). ELISA . PubMed: 20812844
- Davies PL et al. Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax 65:246-51 (2010). WB ; Human . PubMed: 20335295
- Kang W et al. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther 16:229-39 (2009). ELISA . PubMed: 18923452
- Mahadeva R et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 166:377-86 (2005). PubMed: 15681822